Axonics Inc Revenue Growth Rates (AXNX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Axonics Inc   (NASDAQ: AXNX)
 

AXNX's Revenue Growth by Quarter and Year

Axonics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AXNX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 115.65
2nd Quarter June 114.14
1st Quarter March 91.25
FY 321.04

AXNXs Annual Revenue
Axonics Inc 's Revenue in the fiscal year 2023 $ 365.55 millions
Axonics Inc 's Revenue in the fiscal year 2022 $ 273.70 millions
Axonics Inc 's Revenue in the fiscal year 2021 $ 180.29 millions
Axonics Inc 's Revenue in the fiscal year 2020 $ 111.54 millions
Axonics Inc 's Revenue in the fiscal year 2019 $ 13.82 millions




AXNX Revenue third quarter 2024 Y/Y Growth Comment
Axonics Inc reported Revenue improvement of 25.57% year on year in the third quarter 2024, to $ 115.65 millions, this is lower than Axonics Inc 's recent average Revenue surge of 394.23%.

Looking into third quarter 2024 results within Medical Equipment & Supplies industry 45 other companies have achieved higher Revenue growth. While Axonics Inc ' s Revenue rise of 25.57% ranks overall at the positon no. 595 in the third quarter 2024.


AXNX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 27.92 % 61.69 % 52.79 %
3rd Quarter September 25.57 % 30.86 % 50.03 % 33.12 %
2nd Quarter June 22.88 % 34.66 % 50.38 % 201.58 %
1st Quarter March 29.16 % 45.91 % 40.88 % 30.68 %
FY   - 33.56 % 51.81 % -

Financial Statements
Axonics Inc 's third quarter 2024 Revenue $ 115.65 millions AXNX's Income Statement
Axonics Inc 's third quarter 2023 Revenue $ 92.10 millions Quarterly AXNX's Income Statement


AXNX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 19.34 % 22.08 % 13.28 %
3rd Quarter September 1.32 % -0.85 % 2.03 % 2.27 %
2nd Quarter June 25.08 % 31.48 % 42.46 % 33.46 %
1st Quarter March -16.98 % -17.77 % -8.88 % -1.18 %
FY (Year on Year)   - 33.56 % 51.81 % -


Back to AXNX Growth rate Comparisons >> Back to AXNX Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #46
Healthcare Sector #168
Overall #595

Revenue Y/Y Growth Statistics
High Average Low
2592.36 % 394.23 % 22.87 %
(Sep 30 2020)   (Sep 30 2024)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #46
Healthcare Sector #168
Overall #595
Revenue Y/Y Growth Statistics
High Average Low
2592.36 % 394.23 % 22.87 %
(Sep 30 2020)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Axonics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
659.82 % 54.41 % -42.15 %
(Dec 31 2019)  


AXNX's III. Quarter Q/Q Revenue Comment
Axonics Inc achieved in the III. Quarter 2024 below company average Revenue growth of 1.32% quarter on quarter, to $ 115.65 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -0.85% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue quarter on quarter growth. While Axonics Inc 's Revenue growth quarter on quarter, overall rank is 1974.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #324
Overall #1974
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #324
Overall #1974
Revenue Q/Q Growth Statistics
High Average Low
659.82 % 54.41 % -42.15 %
(Dec 31 2019)  


AXNX's III. Quarter Q/Q Revenue Comment
Axonics Inc achieved in the III. Quarter 2024 below company average Revenue growth of 1.32% quarter on quarter, to $ 115.65 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -0.85% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue quarter on quarter growth. While Axonics Inc 's Revenue growth quarter on quarter, overall rank is 1974.


Axonics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 430.95 $ 407.41 $ 386.16 $ 365.55 $ 341.57
Y / Y Revenue Growth (TTM) 26.17 % 27.38 % 30.49 % 33.56 % 41.78 %
Year on Year Revenue Growth Overall Ranking # 301 # 179 # 25 # 94 # 349
Seqeuential Revenue Change (TTM) 5.78 % 5.5 % 5.64 % 7.02 % 6.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 1353 # 991 # 356 # 740 # 182


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Axonics Inc 's cumulative twelve months Revenue were $ 431 millions, company would post below average annual Revenue growth of 6.79% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Axonics Inc 's Revenue growth from the 114.14% growth in Jun 30 2024.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 179 to 301.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 87
Healthcare Sector # 99
Overall # 301

Revenue TTM Y/Y Growth Statistics
High Average Low
2028.08 %
 236.43 %
26.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 271
S&P 500 # 1353
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Axonics Inc 's cumulative twelve months Revenue were $ 431 millions, company would post below average annual Revenue growth of 26.17% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Axonics Inc 's Revenue growth from the 114.14% growth in Jun 30 2024.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 179 to 301.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 87
Healthcare Sector # 99
Overall # 301

Revenue TTM Y/Y Growth Statistics
High Average Low
2028.08 %
236.43 %
26.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 271
S&P 500 # 1353




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AXNX's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Genedx Holdings Corp 44.26%$ 44.255 millions
Harrow Inc 43.98%$ 43.982 millions
Electrocore Inc 43.94%$ 43.944 millions
Puma Biotechnology Inc 43.53%$ 43.528 millions
Ufp Technologies Inc 43.45%$ 43.447 millions
Avita Medical Inc 43.25%$ 43.247 millions
Scilex Holding Company42.69%$ 42.691 millions
Ultragenyx Pharmaceutical Inc 42.27%$ 42.265 millions
Sunshine Biopharma Inc 41.59%$ 41.585 millions
Igc Pharma Inc 41.58%$ 41.581 millions
Trisalus Life Sciences Inc 41.44%$ 41.440 millions
Lifemd Inc 41.09%$ 41.095 millions
Clearpoint Neuro Inc 40.96%$ 40.958 millions
Personalis Inc 40.89%$ 40.894 millions
Sarepta Therapeutics Inc 40.79%$ 40.792 millions
Inmed Pharmaceuticals Inc40.23%$ 40.225 millions
American Oncology Network Inc 39.84%$ 39.837 millions
Neuraxis Inc 39.62%$ 39.619 millions
Castle Biosciences Inc 39.50%$ 39.499 millions
Lifeward ltd 39.18%$ 39.178 millions
Intra cellular Therapies Inc 39.00%$ 38.996 millions
C4 Therapeutics Inc 38.75%$ 38.746 millions
Lensar Inc 38.22%$ 38.224 millions
Amicus Therapeutics inc 37.72%$ 37.719 millions
Equillium Inc 37.10%$ 37.103 millions
Hyperfine Inc 36.91%$ 36.911 millions
Mannkind Corporation36.73%$ 36.732 millions
Lyell Immunopharma Inc 36.00%$ 36.000 millions
Hyperion Defi inc 35.64%$ 35.643 millions
Sanara Medtech Inc 35.39%$ 35.394 millions


About Axonics Inc Revenue Growth Rates (AXNX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Axonics Inc (CIK 1603756).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001603756-24-000077
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Axonics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.